Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Graft-Versus-Host Disease

Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors

Summary:

In this open single-centre phase II study, MMF was added on day +10 after allogeneic transplantation to standard immunosuppressive prophylaxis consisting of cyclosporine and methotrexate to decrease the incidence of GvHD. In all, 30 patients aged 20–59 years with advanced haematological malignancies received an unmanipulated blood-stem-cell graft (median of 8.5 × 106 CD34+ and 349 × 106 CD3+ cells per bodyweight) from matched unrelated (n=26), or mismatched donors (n=4). Prior to transplantation, 13 patients underwent fractionated total body irradiation and cyclophosphamide, one patient additional etoposide. In all, 16 patients received reduced conditioning of fludarabin, busulfan, and antithymocyte globulin. All patients engrafted in a median of 12 days, and 19 developed acute GvHDII, including two patients with GvHD III and three with GvHD IV. Subsequently, nine patients developed limited and two patients extensive chronic GvHD. With a median follow-up of 28 months, the overall survival is 53.3% and disease-free survival 50%, respectively. Only two deaths were due to GvHD IV. Out of 13 patients, 10 being CMV IgG positive became positive for pp65. In conclusion, this MMF schedule seems to be safe and feasible in the prophylaxis of severe acute GvHD for high-risk patients, restricted by an increased risk for reactivating CMV in seropositive patients.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1

References

  1. Fulton B, Markham A . Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 1996; 51: 278–298.

    Article  CAS  PubMed  Google Scholar 

  2. Sollinger HW . Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225–232.

    Article  CAS  PubMed  Google Scholar 

  3. Kobashigawa J, Miller L, Renlund D et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate mofetil investigators. Transplantation 1998; 66: 507–515.

    Article  CAS  PubMed  Google Scholar 

  4. Bullingham R, Monroe S, Nicholls A et al. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996; 36: 315–324.

    Article  CAS  PubMed  Google Scholar 

  5. Jenke A, Renner U, Richte M et al. Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation. Clin Transplant 2001; 15: 176–184.

    Article  CAS  PubMed  Google Scholar 

  6. Bornhauser M, Schuler U, Porksen G et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 1999; 67: 499–504.

    Article  CAS  PubMed  Google Scholar 

  7. Basra N, Blau WI, Kiehl MG et al. Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients. Clin Transplant 2000; 14: 121–126.

    Article  Google Scholar 

  8. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for the prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–735.

    Article  CAS  PubMed  Google Scholar 

  9. Bornhäuser M, Kiehl M, Siegert W et al. Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis. Br J Hematol 2001; 115: 119–124.

    Article  Google Scholar 

  10. Beelen DW, Elmaagacli A, Müller KD et al. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone in the development of acute graft-versus-host disease after marrow transplantation in patients with hematological malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood 1999; 93: 3267–3275.

    CAS  PubMed  Google Scholar 

  11. Thomas ED, Storb R, Clift RA et al. Bone-marrow transplantation (first and second of two parts). N Engl J Med 1975; 292: 832–843, and 895–902.

    Article  CAS  PubMed  Google Scholar 

  12. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinico-pathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  CAS  PubMed  Google Scholar 

  13. Basra N, Fauser AA . Safety profile of mycophenolate mofetil. Bone Marrow Transplant 2000; 25: 1362–1363.

    Article  Google Scholar 

  14. Nademanee A, Schmidt GM, Parker P et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood 1995; 86: 1228–1234.

    CAS  PubMed  Google Scholar 

  15. Schetelig J, Kröger N, Held TK et al. Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease. Haematologica 2002; 87: 299–305.

    PubMed  Google Scholar 

  16. Niederwieser D, Maris M, Shizuru JA et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620–1629.

    Article  CAS  PubMed  Google Scholar 

  17. Blaha P, Bigenzahn S, Koporc Z et al. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood 2003; 101: 2886–2893.

    Article  CAS  PubMed  Google Scholar 

  18. Kiehl MG, Shipkova M, Basra N et al. New strategies in GVHD prophylaxis. Bone Marrow Transplant 2000; 25 (S2): 16–19.

    Article  Google Scholar 

  19. Basra N, Blau WI, Willenbacher W et al. New strategies in the treatment of graft-versus-host disease. Bone Marrow Transplant 2000; 25: 12–15.

    Article  Google Scholar 

  20. Vogelsang GB, Arai S . Mycophenolate mofetil for the prevention of graft-versus-host disease following stem cell transplantation: preliminary findings. Bone Marrow Transplant 2001; 27: 1255–1262.

    Article  CAS  PubMed  Google Scholar 

  21. Feinstein LC, Sandmaier BM, Hegenbart U et al. Non-myeloablative allografting form human leukocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. Br J Hematol 2003; 120: 281–288.

    Article  Google Scholar 

  22. Nash RA, Antin JH, Karanes C et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062–2068.

    CAS  PubMed  Google Scholar 

  23. Przepiorka D, Anderlini P, Saliba R et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001; 98: 1695–1700.

    Article  CAS  PubMed  Google Scholar 

  24. Boeckh M, Leisenring W, Riddel SR et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003; 101: 407–414.

    Article  CAS  PubMed  Google Scholar 

  25. Junghanss C, Boeckh M, Catrer RA et al. Incidence and outcome of cytomegalovirus infection following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002; 99: 1978–1985.

    Article  CAS  PubMed  Google Scholar 

  26. Hambach L, Stadler M, Dammann E et al. Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 29: 903–906.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to C Kasper.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kasper, C., Sayer, H., Mügge, L. et al. Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors. Bone Marrow Transplant 33, 65–69 (2004). https://doi.org/10.1038/sj.bmt.1704299

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704299

Keywords

  • graft-versus-host disease
  • mycophenolate mofetil
  • MMF
  • allogeneic stem cell transplantation

This article is cited by

Search

Quick links